ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Rapport
Temps Différé Nasdaq  -  22:00 24/06/2022
12.28 USD   +0.74%
23/06VENTE PAR DES INITIÉS : Allogene Therapeutics
MT
08/06Le traitement potentiel du cancer d'Allogene obtient la désignation de thérapie avancée de médecine régénérative de la FDA
MT
08/06Allogene Therapeutics, Inc. annonce que la FDA a accordé la désignation de thérapie avancée en médecine régénérative (RMAT) à ALLO-501A pour le lymphome à grandes cellules B
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur ALLOGENE THERAPEUTICS, INC.
23/06INSIDER SELL : Allogene Therapeutics
17/06ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
13/06TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
08/06Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
08/06Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy..
08/06Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy ..
08/06Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy ..
08/06Allogene Therapeutics, Inc. Announces the FDA Granted Regenerative Medicine Advanced Th..
08/06Allogene Therapeutics Gets RMAT Designation for ALLO-501A Lymphoma Treatment
27/05ALLOGENE THERAPEUTICS : ALLO May 2022 Corporate Presentation
19/05Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
19/05Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
10/05TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
10/05Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
09/05Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
04/05TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
04/05ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
04/05ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
04/05ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
04/05Allogene Therapeutics Reports First Quarter 2022 Financial Results
04/05Allogene Therapeutics Reports First Quarter 2022 Financial Results
04/05Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
28/04Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
28/04Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
28/04Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective M..
27/04Allogene Secures FDA's Orphan Drug Designation for Multiple Myeloma Drug Candidate
27/04Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
27/04Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
27/04Allogene Gets FDA Orphan Designation for ALLO-605 in Multiple Myeloma
25/04ALLOGENE THERAPEUTICS : ALLO April 2022 Corporate Presentation
14/04Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Ta..
14/04Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility ..
14/04Allogene Therapeutics Unveils Cell Forge 1, A Uniquely Designed Manufacturing Facility ..
13/04Allogene Therapeutics Says Preclinical Data Show ALLO-316 Has Potential to Treat Solid ..
13/04Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candi..
12/04Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
24/03Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea..
23/03Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Hea..
10/03Allogene Therapeutics Receives FDA Fast-Track Designation for ALLO-316 to Treat Renal C..
10/03Allogene Gets FDA Fast-Track Designation for ALLO-316 in Renal Cell Carcinoma
10/03Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Can..
10/03Allogene Therapeutics, Inc. Receives FDA Fast Track Designation for its First Solid Tum..
01/03Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Re..
24/02Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P..
23/02ALLOGENE THERAPEUTICS : ALLO February 2022 Corporate Presentation
23/02TRANSCRIPT : Allogene Therapeutics, Inc., Q4 2021 Earnings Call, Feb 23, 2022
23/02ALLOGENE THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
23/02ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
23/02ALLOGENE THERAPEUTICS : Q4 Earnings Snapshot
23/02Allogene Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 3..
23/02Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and P..
23/02Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
16/02Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on F..
11/02Cellectis' Licensed Partner, Allogene Therapeutics Announces Removal of FDA Clinical Ho..
08/02ALLOGENE THERAPEUTICS : ALLO January 2022 Corporate Presentation
26/01Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Confere..
18/01Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical H..
14/01INSIDER BUY : Allogene Therapeutics
14/01INSIDER BUY : Allogene Therapeutics
12/01Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
11/01ALLOGENE THERAPEUTICS : JPM Presentation 2022
11/01TRANSCRIPT : Allogene Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Confe..
11/01Allogene Therapeutics Enters Into Cancer Therapy Collaboration With Antion Biosciences
11/01Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clini..
11/01Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement wi..
11/01Cellectis' Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical ..
11/01US FDA Lifts Hold on Cellectis Partner's Clinical Studies of Cancer Therapy
11/01Antion Biosciences SA announced that it expects to receive funding from Allogene Therap..
10/01TRANSCRIPT : Allogene Therapeutics, Inc. - Special Call
10/01Allogene Therapeutics' T Cell Trials Off FDA Clinical Hold
10/01ALLOGENE : FDA Lifts Clinical Hold Across AlloCAR T Studies
10/01Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T&trade..
10/01Allogene Therapeutics, Inc. Announces U.S. Food and Drug Administration Removes Clinica..
04/01Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conf..
2021ALLOGENE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (fo..
1  2  3  4  5  6Suiv.
Prochain événement sur ALLOGENE THERAPEUTICS, INC.